Just Part of Frank’s Story

TEDxBigApple – Robert Langer
Biomaterials for the 21st Century

TEDxBoston – Frank Reynolds
Changing the Face of Neuroscience Forever

 “If we go to doctors right now and say ‘don’t overprescribe’ without providing some mechanisms for people in these communities to deal with the pain that they have or the issues that they have, then we’re not going to solve the problem”. – President Obama

“Although thick with opiate pipelines, biotech and pharma industry pipelines for non-opiate, non-addictive pain treatment are thin to non-existent” – Frank Reynolds, Founder and CEO PixarBio Corp

NeuroRelease is the only non-opiate product in process at the US FDA that can treat post-op pain treatment LONGER THAN 5 DAYS and we last 14 days defeating Rebound Pain.

PixarBio will lead the Non-Opiate Revolution around Non-Addictive Pain treatments.

NeuroRelease FDA approval is expected in early 2019, mitigates sensory (pain) signaling without effecting locomotion (moving) signals and we have the potential to replace morphine in the clinic.

  • To defeat Rebound Pain over 40 surgical procedures require 14 days of post-op pain treatment
  • 100% of surgeons prefer non addictive pain treatments over morphine
  • Over 90% of patients prefer non-addictive post op pain treatment over morphine

NeuroRelease is expected to receive FDA approval for post-op pain in early 2019, and with our growing team of industry experts NeuroRelease will create a new clinical franchise in medicine around NeuroRelease’s pain product pipeline.

More importantly, we’ll change the way medicine is delivered throughout the world.

Lead pain treatments will last up to 14 days, 7 days, 90 days, for the clinic and 4-8 hours for dentistry.

Clinical Studies

As a 505b2 product going through the FDA, each study will have two phase studies (not three) to receive FDA Approval by early 2019.

Each study will have two phases for FDA Approval.

  • Small Nerve- Shoulder Surgery Pain Study with a total of 260 patients
  • Large Nerve- Knee Replacement Pain Study with a total of 260 patients

 

These two studies will permit the NeuroRelease to be Marketed as a nerve block anywhere in the body

PixarBio Answers Society Mandate for Non addictive Pain Treatment

Over 40 different surgical procedures, where 50% of more of surgical physicians need a 14 day post op treatment

  • NeuroRelease Meets Societies Unmet Medical Need to replace Opiates
  • Clinic based addiction is whipped out for NeuroRelease patients.
  • NeuroRelease patients go home quickly reducing hospital stay
  • Patients begin physical therapy and rehabilitation quickly.

As NeuroRelease has evolved we have already extended NeuroRelease to spinal cord injury, Epilepsy, and Parkinson’s disease and the platform demonstrates great promise.

Website Forward-Looking Statement

This website includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of PixarBio’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio’s Corp HQ at 200 Boston Ave, Suite 1875 in Medford, MA 02155.

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.